T2D injectables: 3. Intensifying to first injectable therapy in patients with established ASCVD
You need to login to participate in this education.
This education is accredited: RACGP 3 CPD, ACRRM 2.00 CME PD.
This is one module of the T2D injectables series of education, which is also available as the 5-hour Accredited CPD Activity Rethinking first injectable therapies in type 2 diabetes: A practical approach.
This education module takes a case-study based look at the management of a type 2 diabetes patient with established ASCVD. Featuring expert video commentary, participants will use the decision cycle from the ADA/EASD consensus guidelines for T2D to work through a hypothetical case study. This module also discusses GP-related causes of clinical inertia, as well as additional patient factors such as obesity, low health literacy and diabetes distress.
On completion of this education activity participants will be able to:
- Apply principles of patient-centred glycaemic management in type 2 diabetes to help choose a suitable first injectable therapy for a patient with uncontrolled type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD).
- Outline evidence for the benefit of selected GLP-1 RAs to reduce mortality, heart failure and progression of renal disease in the setting of established ASCVD or CKD in type 2 diabetes.
- Explain what the considerations are when selecting and monitoring injectable glucose-lowering agents in elderly and/or frail patients with type 2 diabetes.
- Use standardised tools to help identify and assess diabetes distress in patients and understand how to address diabetes distress as part of the management plan in type 2 diabetes.
This activity is sponsored by Eli Lilly Australia.
|T2D injectables: 3 - Education|
|T2D injectables: 3 - Evaluation|